Genus PLC Board Appointment (1019P)

TIDMGNS

RNS Number : 1019P

Genus PLC

24 May 2018

For Immediate Release

24 May 2018

Genus plc

Board Appointment

Genus (LSE: GNS), a leading global animal genetics company, is pleased to announce the appointments of Lesley Knox and Professor Ian Charles to the Board as Non-Executive Directors, with effect from 1 June 2018 and 1 July 2018 respectively.

Lesley Knox brings a wealth of international, strategic and financial services experience. Lesley has held several Non-Executive Directorships and is currently Non-Executive Director and Chair of the Remuneration Committee at Legal & General Group plc, Non-Executive Director for Thomas Cook Group plc, and also Chair of Grosvenor Group. She previously served on the Board of both Centrica plc and SAB Miller plc as Non-Executive Director and Chair of the Remuneration Committee. Lesley spent over 17 years in corporate finance with Kleinwort Benson and then as a founder director of British Linen Advisers. She was also head of institutional asset management at Kleinwort Benson and has advised a wide range of companies which included manufacturers and distributors of food products including poultry and poultry breeding companies.

Ian Charles is Director of the Quadram Institute, Norwich, UK and was previously Director of the ithree institute, University of Technology, Sydney, Australia. An entrepreneurial scientist, he is co-founder and Board Director of Auspherix, and was co-founder and CSO of Arrow Therapeutics. Ian's current research focus is in the area of infectious diseases, the microbiome, and its impact on health and well-being. He has over 30 years' experience in academic and commercial research organisations, including The Wolfson Institute for BioMedical Research at University College London and Glaxo Wellcome.

Commenting on the appointments, Bob Lawson, Chairman of Genus, said:

"We are delighted to welcome Lesley Knox and Ian Charles to the Board. Lesley's wide-ranging Non-Executive experience in diverse settings will complement the Board, and her experience and insights will assist in the oversight and the continued execution of the Company's strategic goals. Ian's deep scientific expertise and experience will enable the Board to seamlessly transition from the loss of Professor Duncan Maskell who, as previously announced, leaves the Board after the Company's Annual General Meeting in November to commence his work as the Vice-Chancellor of the University of Melbourne, Australia."

There are no further details to be disclosed in respect of Lesley Knox or Ian Charles under paragraph 9.6.13R of the Listing Rules of the UK FCA.

For further information please contact:

Genus plc

   Bob Lawson, Chairman                                               Tel: 01256 345970

Karim Bitar, CEO

Buchanan

   Charles Ryland / Sophie Wills                                     Tel:  0207 466 5107

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

BOASELFADFASEII

(END) Dow Jones Newswires

May 24, 2018 02:02 ET (06:02 GMT)

Genus (LSE:GNS)
Historical Stock Chart
From Oct 2024 to Nov 2024